Hepatitis C New Drug Research And Liver Health
  • HCV News Of The Day
    • 2013/HCV Drugs News Digest
    • HCV Drugs: News Digest>
      • News Archive
      • Liver HCV : Specialty news digest
  • 2013 - Breaking Conference Reports/Hepatitis C
    • Breaking Conference Reports >
      • EASL 2012 Meeting Summary>
        • EASL Summary Of The 2011 March Meeting
      • AASLD- Nov 2011 Annual Meeting>
        • Conference Archive
  • Blog: New HCV Drug Updates
  • HCV FAQ
  • HCV: Newly Diagnosed?
    • Challenges-issues in managing hepatitis C
    • Ask Me A Question About Hepatitis C
  • What to do with a positive hepatitis C test
  • 2013-HCV Abstract Corner
    • HCV Abstract Corner>
      • Archive; Abstract Corner
  • 2013-Hepatitis C Full Text Articles
    • Hepatitis C Treatment Complete Studies 2012>
      • Potential new method to block the lifecycle of the Hepatitis C virus
      • Hepatitis C Treatment Complete Studies 2011
  • 2013/HCV Multimedia Videos Podcasts
    • Multimedia/Videos-Podcasts>
      • Watch How Hepatitis C Protease Inhibitors Work>
        • Multimedia; Archives Videos and Podcasts
  • 2013 Stem Cell News and Research
    • Liver-2012 Stem Cell Updates
    • Liver: 2011 Stem Cell Updates
    • What Are Stem Cells?>
      • Future applications of human stem cells
  • Recommended; Stem Cell Blogs
  • Understanding Hepatitis C
  • Natural History Of HCV
    • A 20-year cohort study on the natural history of untreated HCV infection
  • Hepatitis C Disease Progression
    • NIH scientists identify likely predictors of hepatitis C severity
    • HCV Epidemiology, Diagnosis and Disease Progression
    • Hepatitis C may increase deaths from both liver-related and other diseases>
      • Mortality in advanced HCV /long-term peginterferon
    • Host Factors on Management of HCV
  • Transmission
    • How Soon To Initiate HCV Therapy After Transmission
    • Does the Hepatitis C virus survive in dried blood ?
    • Viral Load Tied to Vertical Transmission of Hepatitis C
    • Hey Can I Get Hep C From......
    • HCV infections transmitted via a clinical setting
    • What Should I Do If I Get A Needlestick
  • How are the different types of hepatitis transmitted
    • New challenges in viral hepatitis
    • Hepatitis A virus infection in high-risk subjects
  • Your Liver Functions
  • Liver Function Tests
    • HCV-Persistently Normal (ALT) Alanine Aminotransferase Levels
    • Hey, I have a question about hcv tests and my liver
    • ALT used to separate those infected with HCV from those at low risk of liver disease
  • Lab Reports
  • HCV Viral Load Test
  • Liver Biopsy/Noninvasive Tests
    • Is there still a role for liver biopsy in managing hepatitis C virus infections?
    • Overview of Liver Biopsy Procedure
    • Three Algorithms of Non-invasive Markers of Fibrosis in Chronic Hepatitis C
    • FibroScan comparison to liver fibrosis biomarkers
  • Chronic HCV Symptoms
    • Fatigue and HCV
    • Sleep Disturbance in Chronic HCV
    • Skin Rash/Hepatitis C
    • Liver Disease: Bone Loss "It Ain't Like Menopause!"
  • HCV Neuropsychiatric symptoms-“brain fog”
    • HCV-Related Nervous System Disorders
    • Hepatitis C Virus and the Brain
    • Liver-induced inflammation hurts the brain
    • The Brain on Fire: Inflammation and Depression
  • Conditions Outside The Liver
    • Prevalence of fibromyalgia among patients with chronic hepatitis C
    • Lichen Planus and The Hepatitis C Virus
    • Dermatologic Disorders and Liver Disease
  • Chronic hepatitis C: Treat or wait?
    • Preparing For Treatment>
      • Starting Hepatitis C Treatment: Tips and Information 2011
      • Adherence To HCV Treatment-Review
      • Treating Hepatitis C; What can you do to increase your chance for SVR?
  • Hepatitis C advanced fibrosis: Treat or Wait
  • Approved Treatments for Hepatitis C
    • Adults:Treating Hepatitis C
    • Interferons and hepatitis C virus
  • HCV Treatment Failure Can Still Mean Less Liver Inflammation
  • Protease inhibitors geno-1:New standard of care
    • Treating HCV Genotype 1 In The Real World
    • 2012 - Direct acting antivirals for the treatment of chronic hepatitis C
    • HCV:End of the Beginning-Possibly-Beginning of the End
    • Patients’ Expectations About New HCV Direct-Acting Antivirals Often Unrealistic
    • What Are NS5A inhibitors ?
    • Hepatitis C Treatment Nonresponders
    • New 2011 AASLD guidelines for treating HCV
    • Treating New and Old Therapies>
      • High-grade liver inflammation may predict treatment response
  • HCV Resistance To New And Experimental Drugs
    • Understanding Resistance in Chronic HCV Infection
  • 2012 Future Prospects-Treatment of HCV
    • Advances in the treatment of hepatitis C virus infection.
  • Boceprevir & Telaprevir
    • FDA Telaprevir/Boceprevir Transcript
    • Pocket Guide Telaprevir/Boceprevir
    • Quick Facts- Direct-acting antivirals Telaprevir/Boceprevir
    • Telaprevir Or Boceprevir: What Is My Chance For A Cure?
  • 2013 News/Incivek (Telaprevir)
    • News/Telaprevir>
      • Telaprevir-IFN/ribavirin Hints at Response
      • Telaprevir FDA Approval>
        • Help-How Do I Take Incivek-telaprevir ?
        • Quick Study Of Telaprevir
        • Cost Of Treating With Telaprevir
  • 2013 News/Victrelis (Boceprevir)
    • News/ Boceprevir>
      • VICTRELIS-Boceprevir: Prescribing-Medication Guide
      • 2011;Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
      • 2011-Boceprevir for Untreated Chronic HCV Genotype 1 Infection
  • Side Effects-Interferon Free Therapies
  • Drug-Drug Interactions In Triple-Therapy
  • 2013/HCV Triple-therapy Side Effects
    • Boceprevir,Telaprevir Less Side Effects?>
      • 2013-HCV therapy geno 1: management of side-effects
      • Dry Mouth and Treatment >
        • Dry Mouth (Xerostomia)
      • Important updates to PegIntron labeling
      • Peginterferon alfa-2a Drug Interactions
      • HCV Treatment: Peginterferon and Ribavirin Side Effects
  • Genotypes/Treatment
    • Treatment Duration in Hepatitis C Virus Genotype 2/3-infected Patients
    • Impact of IL28B on Liver Histopathology in HCV Genotype 2/3
    • Genotype 3/HCV Treatment
    • HCV-Genotype 5 or 6
    • Hepatitis C-Genotype 4>
      • How to optimize HCV therapy in genotype 4 patients
      • Geno 4-Pioglitazone Decreases HCV Viral Load
    • Telaprevir/Boceprevir *genotype 1,2,3
    • (HCV) genotypes in the severity of liver disease
  • What Is The IL28B gene ?
    • Hepatitis C Test:Likelihood of achieving SVR>
      • IL28B and HCV immune responses
  • Index-Current Hepatitis C Drugs In Development
  • 2013-Interferon Free Combinations
    • Interferon-free combinations
    • 2013-Interferon free therapy w-direct acting antivirals for HCV
  • 2013 Sofosbuvir (GS-7977)
    • GS-7977-Formally PSI-7977 >
      • PSI-7977 peg/riba Geno 2/3 PROTON Trial
  • Sofosbuvir(GS7977)/Simeprevir(TMC435)
    • Interferon-Free Combo PSI-7977-TMC435
  • Sofosbuvir (GS-7977)/Ledipasvir (GS-5885)
  • GS-5885, an NS5A Inhibitor
  • ABT-450/r, ABT-267, ABT-333
  • Faldaprevir (BI 201335) and BI 207127 Interferon-Free
    • NS3/4A protease inhibitor BI201335
  • Miravirsen First MicroRNA-Targeted Drug
  • BMS-790052 (Daclatasvir)
  • Daclatasvir/VX135
  • ALS-2200 (VX-135)
  • BMS-790052/BMS-650032 Interferon-sparing
  • (TMC435) Simeprevir
  • TMC435 monotherapy in HCV genotypes 2-6
  • Simeprevir (TMC435) and TMC647055
  • Simeprevir,TMC647055 and IDX719
  • TMC435-daclatasvir-BMS-790052
  • Danoprevir-RG7227 direct-acting antiviral
  • Mericitabine- Polymerase Nuc
  • Sovaprevir (Formerly ACH-1625)
  • ACH-3102 NS5A inhibitor
  • INCIVEK, VX-222/Ribavirin
  • MK-5172 protease inhibitor
  • HCV/New Drug Pipeline
  • 2013/Hepatitis C Clinical Trials
    • Clinical Trials>
      • Learning About Clinical Trials
      • Boceprevir and Telaprevir Trials>
        • Telaprevir REALIZE STUDY
  • HCV Trials/Discontinued Or On Hold
    • Idenix IDX184-Hepatitis C drug
    • TMC435-BMS-986094-formerly INX-189
  • Women's Health; Treating Hepatitis C
    • Early Menopause and Response to HCV Treatment
  • Hepatitis C in Pregnancy
  • Treating Hepatitis C In Children
    • 2012 Hepatitis C infection in children
    • Autoimmunity/Extrahepatic Manifestations in HCV Treatment-Naïve Children
    • Study-long-term safety/durability of virologic response in paediatric patients who were previously treated w-interferon alfa-2b plus ribavirin for 48 weeks
  • Liver Disease in Elderly Patients
  • Dental considerations in patients with liver disease
    • HCV: Dental management-Diagnosis of extrahepatic manifestations>
      • Dental problems delaying the initiation of interferon
  • Fibrosis
    • Is there a natural way to improve liver fibrosis ?
  • 2013 News/Fibrosis
    • News: Fibrosis
  • Cirrhosis
    • What Is Cirrhosis ?
    • Advanced Liver Disease: What Every HCV Treater Should Know
    • The Patient With Cirrhosis: Don't Miss This
    • Hey, I have a question about cirrhosis
    • Physical Findings Suggestive Of Cirrhosis/Photos
    • Staging Cirrhosis>
      • When the Spleen Gets Tough, the Varices Get Going
    • Management Cirrhosis: How Are We Doing?
    • Cirrhosis Regression
    • Cirrhosis ; Surgery in the Patient with Liver Disease
    • Hepatic Encephalopathy>
      • Varices
      • Ascites
      • Management of ascites
  • 2013 News/Cirrhosis
    • News: Cirrhosis>
      • GI Bleeds: Withholding Transfusions Boosts Survival
  • Liver Transplant
    • New HCV Drugs:Expected Risks-Challenges in Liver Transplant
    • Prevention of hepatitis C recurrence after liver transplantation>
      • Effects of Telaprevir on Cyclosporine and Tacrolimus Pharmacokinetics Make Utility in Post-OLT Setting Uncertain
      • HCV Treatment After Liver Transplant
      • Antivirals Ineffective Against HCV After LT
  • 2013 News/Transplant
    • Liver Transplant News
  • Hepatocellular Carcinoma
    • Audio:Liver Cancer
    • Radioembolisation (RE),Selective Internal Radiation Therapy (SIRT)
    • Diagnosis (markers) of early hepatocellular carcinoma
    • Intrahepatic cholangiocarcinoma
    • Treatment TheraSphere/HCC/primary liver cancer
    • Liver Cancer : Microwave Ablation (MWA)
    • Pain May Predict Liver Cancer Prognosis
    • What Is the Indication for Sorafenib in Hepatocellular Carcinoma?
    • Liver Cysts and Tumors"Two Totally Different Concepts"
    • Interactive map of cancer mortality risk worldwide
  • 2013 News/Liver Cancer
    • Liver Cancer News and Updates
    • Vitamin E may lower liver cancer risk
  • Guidelines Nonalcoholic Fatty Liver Disease (NAFLD)
    • Fatty Liver And HCV>
      • Touching some firm ground in the epidemiology of NASH
      • Ultrasound/Liver Biopsy
      • Fatty Liver and Treatment
      • Liver fibrosis/Fatty Liver
  • 2013-Coffee and Liver Disease
  • Liver Regeneration
  • Liver Health
    • Choline: Great for the Liver
    • Medications for sleep in liver disease
    • The odds of gallbladder disease in Hepatitis C Patients
    • HCV & Gallbladder Disease:
    • Enlarged Spleen
    • HCV And Cardiovascular Risk
  • Nutrition-Herbs-Vitamins
    • Vitamin D and Treatment
    • Liver Disease - The Mediterranean Diet
    • Diet: Cirrhosis>
      • Low-Salt Diet-A Must in Cirrhosis
      • Diet for Liver Disease Low Sodium and More
      • Vitamin B12 supplements may help treat hepatitis
      • Nutrition in end-stage liver disease
      • Cirrhosis; Vitamin K Deficiencies
      • Vitamin D Levels In Cirrhosis
      • Vitamin D could de-stress Liver Disease Treatments
      • Drugs And Cirrhosis
      • Cancer and Berries
  • 2013-Silymarin for HCV infection
  • Milk Thistle
    • 2012-Milk Thistle No Help in Tough Hepatitis C Cases
    • Silymarin-Milk Thistle for NAFLD
    • Milk thistle"- Silibinin in hepatitis C related liver transplantation
    • Milk Thistle is coming to America
    • Caution! Herbs and Nutritional Supplements
  • HCV Drugs: Financial Support
  • HCV Filing For Social Security
  • Hepatitis C: A Rational Call To Arms
    • Hepatitis C; A Forced Legacy
    • Outsourcing:Globalization of the pharmaceutical industry>
      • Inspirational
  • Hepatitis C Links / Best On The Web
    • Chat and Message Boards
  • Whose Website Is This ?
  • Feedback/Contact Us

Ascites

Picture
Ascites, the accumulation of fluid in the abdomen, can be a life-threatening condition 

by Geoff Drushel 

Garth hadn’t been feeling well for some time. At 38, he was feeling run down, and his lower legs hurt all the time. He had been diagnosed with adult-onset diabetes a year or so before, and so he attributed his fatigue, the swelling in his legs and other ailments as just part of the disease. Then his stomach began to swell, like he had eaten too much rich food that wouldn’t digest. It continued that way for several days, but then finally, much to his relief, dissipated. Three months later, however, it was back, and this time it was worse. Garth felt like he was going to pop.


The swelling in Garth’s abdomen was increasingly uncomfortable, and it wouldn’t go away. His skin stretched tightly across his stomach area, his naval lay flat – hardly there at all – and his flanks bulged. Working was difficult to say the least, and despite his rather large appearance and continued weight gain, he had little to no appetite. Breathing at times was difficult. Fed up, both with his condition and the constant pleas of his wife to see a doctor, Garth grudgingly made an appointment.


The diagnosis

Immediately upon seeing the doctor, Garth was referred to a gastroenterologist who took one look at him and said, “You’ve got ascites.” Finally, a diagnosis, he thought. It’s only ascites. Then it hit him. What in the world is ascites? Garth had never heard of this condition; all he knew was that it was painful. He wanted to know what could be done.

The doctor told Garth that he would need a paracentesis, a procedure whereby a needle is inserted into the peritoneum, or lining of the gut, to drain off the ascitic fluid that has accumulated. Fine, he thought. They’ll drain off the fluid, and everything will return to normal. What Garth didn’t know was that the ascites he was experiencing was a common symptom of a much larger problem – one which had not yet been diagnosed. Garth also didn’t know that the fluid that had been drained from him would soon return and that he would be back in the hospital again for a repeat performance, one of many to come.

But what was causing this massive fluid buildup? Why suddenly, having not yet reached 40, was Garth experiencing these symptoms? The doctors seemed to think at first that the abnormal accumulation of fluid in Garth’s abdomen (ascites) had been caused by cirrhosis of the liver, which had been brought about by Garth’s admittedly heavy drinking. And it was natural for the doctors to assume that Garth’s past alcohol consumption was behind it all, since cirrhosis is responsible for 80 percent of all instances of ascites (cancer accounts for another 10 percent and the other incidents are brought about by several other causes, including heart failure, tuberculosis, pancreatic disease and hemodialysis).

While talking to his boss one day about some of the problems he was experiencing, Garth’s boss asked a very straightforward question that had never occurred to Garth or the doctors treating him at the time. “Have you been tested for hepatitis C?” she asked. Well, he thought, surely they would have tested for things like that considering all of the blood they had drawn. But Garth asked the doctors anyway and learned to his surprise that, no, they had not tested him for hepatitis C. It simply had not occurred to them either, and even though they seemed dismissive of the request, they ordered the test along with some others they hoped would lead them to the cause of this most bothersome affliction. “Bingo!” the doctor announced proudly at Garth’s next appointment. “You’ve got hep C.”Now, not only was Garth suffering from this terrible fluid buildup, he had hepatitis C as well, a disease he knew as little about as he did ascites. “What’s next,” he thought. If only he had known.

By the time a hepatitis C patient develops ascites, as was the case with Garth, the damage to the liver, in the form of scarring known as fibrosis, has progressed to the point where cirrhosis is beginning to occur. The flow of blood through the liver is significantly impeded as a result. The blood begins to back up in the portal vein like a clogged pipe (a condition known as portal hypertension). At the same time, low levels of albumin (the glue that holds blood together) in the blood change the pressure inside the blood vessels, prompting osmosis to occur. Blood fluids simply begin to ooze out of the higher-pressure vessels and into the lower-pressure abdomen. Ascites is the result.

As long as the patient is “compensated,” the ascites will not be present, but as the liver decompensates and these various mechanisms previously described begin to occur, the fluid builds up. So for Garth and many others with this condition, the prognosis is not very good. While it can be treated with diuretics, including spironolactone (Aldactone) and furosemide (Lasix) and periodic paracenteses to rid the body of the fluid, the condition often remains persistent and the possibility of complications arising from it, most notably an infection of the fluid known as spontaneous bacterial peritonitis, increases.
“Unfortunately, treatment of ascites will not improve the functioning of the liver, nor will it improve one’s prognosis,” says Melissa Palmer, M.D., a hepatologist and author who practices in Long Island, N.Y. “The development of ascites is a serious complication of cirrhosis that requires prompt evaluation and treatment. It indicates that a person no longer has compensated cirrhosis. Rather, he or she is considered to have decompensated cirrhosis, which means that the body can no longer ‘compensate’ for the extensive scarring (cirrhosis) that has occurred in the liver.

“People with any form of decompensated cirrhosis, whether from ascites, esophageal varices, portal gastropathy and/or encephalopathy, should be evaluated for liver transplantation,” Dr. Palmer says. “The chances of a person’s living one year drops from greater than 90 percent to less than 50 percent once ascites has developed. Therefore, once ascites has developed, liver transplantation should always be considered.”

Ascites can be successfully treated so that it goes away. However, most patients will have the tendency to develop ascites again once it has occurred, and treatment of ascites will not improve the functioning of the liver, nor will it improve one’s prognosis, according to Dr. Palmer. “But treatment of ascites is important,” she adds. “First, it improves the quality of life of the cirrhotic patient. And second, spontaneous bacterial peritonitis (SBP), a life-threatening infection of the ascitic fluid, will not occur if ascites is not present.”

 What’s on tap?

For those with ascites that cannot be controlled through diuretics, some other options exist, although there are increased risks with these procedures. For most, including Garth, it means getting drained of the fluid, or “tapped” in clinical parlance, until such time as the patient improves, receives a transplanted liver or dies.

John Hoef, a physician’s assistant at St. Luke’s Center for Liver Disease in Houston’s sprawling medical center, has been performing paracenteses on patients for the past 12 years. Hoef says he probably does five to 10 “taps” a week and has done hundreds over the years. Garth is one of his patients. He has had more than 40 such procedures performed on him over a four-year period. Hoef says Garth is an unusual case in that he has been treating him for so long. Most patients, he says, either get a transplant within a few years or, sadly, die while waiting for a liver, as is the case with about 25 percent of all those on the liver transplant list.

A typical paracentesis takes about 30 to 45 minutes to perform, Hoef says, and removes around 4 to 6 liters of fluid on average, although it varies case by case. “Everyone is a little different, but I always tell patients not to obsess about the fluid because it’s just going to come back anyway,” he says. “We do it mainly for comfort. If a patient gets the typical back pain and is short of breath and can’t eat and can’t sleep, then we do the procedure to relieve all that. Some people need it once a week, some twice a week, but most people need it every couple of weeks. Some can go longer.”

Hoef says he has drained as much as 13 liters from a patient, but, he adds, that’s not typical. Garth says he has had as much as 10.5 liters drained from him, which amounts to about 22 pounds of fluid filling more than five large, 2-liter bottles. He currently averages about 5 or 6 liters each time he is tapped, which he does monthly at the medical center.

 The procedure

After swabbing the lower abdomen with betadine, an antiseptic, a local anesthetic (typically lidocaine) is injected in the area to numb it, according to Hoef. Then, a larger needle is inserted with a catheter attached. The needle is slipped out, with the catheter left intact, and the other end of the catheter is inserted into one of the vacuum-sealed bottles. The fluid rapidly begins to drain from the abdomen into the bottle. When the bottle is full, the catheter is closed off temporarily while another bottle is prepared, and the procedure continues until the fluid is mostly drained. Once this occurs, the needle is removed, the area is cleaned again and a bandage is placed over the small incision where the catheter/needle was inserted. A few minutes of recovery, and the patient is free to go, although some dizziness and a general loss of energy may impede the patient’s ability to leave right away or to operate a motor vehicle.

In some hospitals or clinics, the process can take longer depending on the facility’s protocol. Some provide the patient with pain relief (typically Valium or Demerol), which can take longer to recover from, and many require that the patient stay for an albumin drip to replace that lost from the procedure. This also requires a longer recovery period since it can take a couple of hours to slowly drip the proper amount of albumin into the body through an IV.

While the procedure generally is done in an outpatient setting, there are, of course, risks, including accidental perforation of the bowel requiring immediate hospitalization. But most medical personnel agree that the alternative of leaving the ascites there is a much larger and much more serious risk. “It’s a risk because some patients with ascites get spontaneous bacterial peritonitis with a high mortality,” says Dr. Bennet Cecil, a hepatologist with a large practice in Kentucky. “And some may get hepatorenal syndrome, where the kidneys shut down causing death.” Either way, he says, it’s a good idea to rid the body of ascites.

For Garth and many in his position, it’s simply a matter of getting used to the uncomfortable procedure and used to the fact that the condition likely will persist unless the liver is able through treatment to repair itself or, in the alternative, a transplant is performed. “I know I can control it to a certain degree, but I don’t think I’ll ever get rid of it totally unless I get a transplant, which I can’t say I’m looking forward to,” Garth says. “For me, it’s just part of life – something I have to deal with whether I like it or not. For the record, I don’t.”

http://www.liverhealthtoday.org/viewarticle.cfm?aid=168

Copyright 2010-2013 Hepatitis C New Drug Research And Liver Health